ArticleScientific reports2025
Characterization of ficus hispida fruit extract and assessment of Gallic acid using in Silico and in vitro studies against breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PAMAM dendrimers as efficient drug nanocarriers of natural compounds in breast cancer therapeutics.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study aimed to characterize the phytochemicals in Ficus hispida fruits and evaluate the anticancer potential of gallic acid against breast cancer using in-silico and in-vitro approaches. The objectives were to identify bioactive compounds using LC-MS, assess gallic acid's binding affinity with breast cancer-related targets via molecular docking and dynamics, and validate its cytotoxicity and apoptotic effects in breast cancer (MDA-MB-231) cells. Ethyl acetate extract of Ficus hispida fruits was prepared via Soxhlet extraction and analyzed using LC-MS/MS. Molecular docking studies were performed to evaluate gallic acid's interactions with breast cancer proteins (2VCJ-Heat shock protein HSP90-alpha, 1P7K-Anti-ssDNA antibody Fab fragment, 5OTE-Serine/threonine-protein kinase MRCK beta), followed by molecular dynamics (MD) simulations for stability analysis. In-vitro cytotoxicity (MTT assay) and apoptosis detection (AO/EB staining, DAPI staining) were conducted on MDA-MB-231 cells. LC-MS analysis identified key phytochemicals, including gallic acid (m/z 169.14), quercetin (m/z 302.33), and β-sitosterol (m/z 414.58). Molecular docking revealed strong binding of gallic acid to Heat shock protein HSP90-alpha (-6.2 kcal/mol), stabilized by hydrogen bonds and hydrophobic interactions. MD simulations confirmed stable protein-ligand complexes with an RMSD of 2.1 Å for the protein and 3.2 Å for the ligand. In vitro studies showed the dose-dependent cytotoxicity of gallic acid against MDA-MB-231 cells, with an IC₅₀ of 15-20 µg/mL and 34.80% viability at 20 µg/mL. Apoptosis was confirmed through nuclear fragmentation and chromatin condensation. Ficus hispida fruits are rich in bioactive compounds, particularly gallic acid, demonstratinga strong binding affinity to breast cancer targets and potent cytotoxic effects against MDA-MB-231 cells. These findings highlight its potential as a therapeutic candidate for breast cancer treatment, warranting further clinical exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.